Drug Approval | January 16, 2026
Zydus receives final approval from USFDA for Eltrombopag Tablets
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Subscribe To Our Newsletter & Stay Updated
